Latest Mauna Kea (MKEAF) Headlines Mauna Kea
Post# of 3
Posted On: 03/10/2014 2:13:45 PM
Latest Mauna Kea (MKEAF) Headlines
Mauna Kea Technologies Receives 510(k) Regulatory Clearance from U.S. FDA for Cellvizio in Urology
Business Wire - Wed Mar 05, 11:26AM CST
--Company makes further progress in positioning optical biopsy technology for new global market opportunities
Mauna Kea Technologies Installs First Cellvizio System in India at Apollo Gleneagles Hospital Kolkata
Business Wire - Wed Feb 19, 11:16AM CST
Regulatory News :
Mauna Kea Technologies Announces Centers for Medicare and Medicaid Services Set New Physician Payments for Upper GI Endoscopy with Cellvizio(R) Optical Endomicroscopy
Business Wire - Mon Jan 13, 10:44AM CST
Regulatory News :
Mauna Kea Technologies Announces Its 2013 FY Sales
Business Wire - Wed Jan 08, 11:54AM CST
--Confirmation of good Asia-Pacific development
Mauna Kea Technologies Partners with the Imperial College of London to Advance Research and Applications of Optical Biopsy with Cellvizio
Business Wire - Thu Dec 12, 11:28AM CST
Regulatory News:
Mauna Kea Technologies : CE Mark for a Complete Range of Probes Dedicated to Urology
Business Wire - Thu Nov 21, 10:45AM CST
Regulatory News :
Mauna Kea Technologies Launches EVA, a Unique Optical Biopsy Operating System Creating a Completely Seamless Customer Experience
Business Wire - Thu Nov 14, 11:14AM CST
Regulatory News :
Mauna Kea Technologies : First Use of Optical Biopsy with Cellvizio(R) in Robotic Assisted Prostatectomy Presented at 31st World Congress of Endourology
Business Wire - Tue Nov 05, 10:45AM CST
Regulatory News:
Mauna Kea Technologies Reports Third Quarter 2013 Sales Up 32 % to EUR2.73m
Business Wire - Thu Oct 10, 11:00AM CDT
--Record Q3 probe sales of 720 KEUR
Mauna Kea Technologies Announces Strong Presence at Asia-Pacific Digestive Week / World Congress of Gastroenterology 2013
Business Wire - Thu Sep 19, 12:30AM CDT
--Live procedures will be performed from Changhai Hospital, The Second Military Medical University, in Shanghai, by world expert Dr. Marc Giovannini
Mauna Kea Technologies Reports Financial Results for Half-Year 2013
Business Wire - Fri Aug 30, 10:45AM CDT
--Stable operating expenses
Mauna Kea Technologies Announces Global Expansion of Cellvizio LAB Distribution Network in Pre-Clinical Research
Marketwire - Thu Jul 25, 10:58AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, has entered several distribution agreements for its line of Cellvizio LAB products, including the Cellvizio Dual Band, for pre-clinical research.
Mauna Kea Technologies Reports Strong Second Quarter 2013 Sales Growth of +33% to EUR 2.5M
Marketwire - Tue Jul 16, 10:45AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced sales results for the fiscal second quarter, ended June 30, 2013.
Mauna Kea Technologies Enters Into Major Cellvizio(R) Distribution Agreement With a Leading Japanese Medical Device Company
Marketwire - Thu Jun 13, 10:45AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, reported that it has entered an exclusive distribution agreement in Japan with AMCO Inc. for a five-year period. This partnership further strengthens Mauna Kea Technologies' ties with the Japanese market, and is a major step forward in the company's efforts to obtain regulatory approval in the world's second largest endoscopy device market after the US.
New Data on Cellvizio Presented at DDW 2013 Suggests That Optical Biopsies May Help Confirm and Rule Out Pancreatic Cystic Tumors*
Marketwire - Wed May 22, 10:45AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced that optical biopsies using a microscope so tiny it fits through a small needle show clear cellular-level images inside pancreatic cysts, which could assist physicians in the diagnosis of pancreatic cystic tumors and help patients with benign cysts avoid unnecessary surgery, according to new data presented at Digestive Disease Week 2013, which concludes here today.
Mauna Kea Technologies Announces Strongest Scientific Exposure Ever With More Than 40 Communications on Cellvizio(R) at Digestive Disease Week 2013
Marketwire - Fri May 17, 12:30AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced that 41 presentations at Digestive Disease Week (DDW) 2013 will highlight the use of optical biopsy across many of the most pervasive diseases in the gastrointestinal tract. Sixteen of the communications will be delivered through oral presentations and seven presentations will focus on needle-based optical biopsies, the newest application of Cellvizio technology that allows physicians to see cellular structures inside pancreatic cysts in the digestive tract in real time. DDW 2013 runs from May 18 to 21 in Orlando.
Mauna Kea Technologies gets FDA approval to market AQ-Flex 19 miniprobe for fine needle aspiration procedures
M2 - Tue Apr 30, 12:01PM CDT
Mauna Kea Technologies (Euronext Paris:MKEA), a medical device company focused on the optical biopsy market, confirmed today that the US Food and Drug Administration (FDA) has cleared the AQ-Flex 19 miniprobe to provide real-time optical biopsies during endoscopic ultrasound-guided fine needle aspiration (EUSFNA) procedures in the digestive tract.
FDA Grants Mauna Kea Technologies 510(k) Clearance to Market AQ-Flex(TM) 19 Miniprobe for Fine Needle Aspiration Procedures
Marketwire - Tue Apr 30, 9:39AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the AQ-Flex(TM) 19 miniprobe to provide real-time optical biopsies during endoscopic ultrasound-guided fine needle aspiration (EUSFNA) procedures in the digestive tract. This represents the sixth U.S. regulatory clearance for Mauna Kea Technologies' Cellvizio or one of its dedicated miniprobes, which already obtained the CE mark in Europe.
Mauna Kea Technologies Announces Highlights of 5th Annual International Conference of Cellvizio(R) Users (ICCU)
Marketwire - Tue Apr 23, 10:45AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced highlights from the 5th Annual International Conference of Cellvizio Users (ICCU) held in Versailles, France, from April 5 to 7. Over 200 international optical biopsy experts -- a 70% increase in attendance over the 2012 meeting -- representing 17 countries and a variety of specialties including digestive endoscopy, pulmonology, urology, surgery, otorhinolaryngology, pathology and pre-clinical research gathered to review and discuss the latest research and impact of optical biopsy on clinical care.
Mauna Kea Technologies Reports First Quarter 2013 Sales Up 11% to EUR 1.8m
Marketwire - Tue Apr 16, 10:45AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced its sales for the first quarter of the year ended March 31, 2013.
Mauna Kea Technologies Receives 510(k) Regulatory Clearance from U.S. FDA for Cellvizio in Urology
Business Wire - Wed Mar 05, 11:26AM CST
--Company makes further progress in positioning optical biopsy technology for new global market opportunities
Mauna Kea Technologies Installs First Cellvizio System in India at Apollo Gleneagles Hospital Kolkata
Business Wire - Wed Feb 19, 11:16AM CST
Regulatory News :
Mauna Kea Technologies Announces Centers for Medicare and Medicaid Services Set New Physician Payments for Upper GI Endoscopy with Cellvizio(R) Optical Endomicroscopy
Business Wire - Mon Jan 13, 10:44AM CST
Regulatory News :
Mauna Kea Technologies Announces Its 2013 FY Sales
Business Wire - Wed Jan 08, 11:54AM CST
--Confirmation of good Asia-Pacific development
Mauna Kea Technologies Partners with the Imperial College of London to Advance Research and Applications of Optical Biopsy with Cellvizio
Business Wire - Thu Dec 12, 11:28AM CST
Regulatory News:
Mauna Kea Technologies : CE Mark for a Complete Range of Probes Dedicated to Urology
Business Wire - Thu Nov 21, 10:45AM CST
Regulatory News :
Mauna Kea Technologies Launches EVA, a Unique Optical Biopsy Operating System Creating a Completely Seamless Customer Experience
Business Wire - Thu Nov 14, 11:14AM CST
Regulatory News :
Mauna Kea Technologies : First Use of Optical Biopsy with Cellvizio(R) in Robotic Assisted Prostatectomy Presented at 31st World Congress of Endourology
Business Wire - Tue Nov 05, 10:45AM CST
Regulatory News:
Mauna Kea Technologies Reports Third Quarter 2013 Sales Up 32 % to EUR2.73m
Business Wire - Thu Oct 10, 11:00AM CDT
--Record Q3 probe sales of 720 KEUR
Mauna Kea Technologies Announces Strong Presence at Asia-Pacific Digestive Week / World Congress of Gastroenterology 2013
Business Wire - Thu Sep 19, 12:30AM CDT
--Live procedures will be performed from Changhai Hospital, The Second Military Medical University, in Shanghai, by world expert Dr. Marc Giovannini
Mauna Kea Technologies Reports Financial Results for Half-Year 2013
Business Wire - Fri Aug 30, 10:45AM CDT
--Stable operating expenses
Mauna Kea Technologies Announces Global Expansion of Cellvizio LAB Distribution Network in Pre-Clinical Research
Marketwire - Thu Jul 25, 10:58AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, has entered several distribution agreements for its line of Cellvizio LAB products, including the Cellvizio Dual Band, for pre-clinical research.
Mauna Kea Technologies Reports Strong Second Quarter 2013 Sales Growth of +33% to EUR 2.5M
Marketwire - Tue Jul 16, 10:45AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced sales results for the fiscal second quarter, ended June 30, 2013.
Mauna Kea Technologies Enters Into Major Cellvizio(R) Distribution Agreement With a Leading Japanese Medical Device Company
Marketwire - Thu Jun 13, 10:45AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, reported that it has entered an exclusive distribution agreement in Japan with AMCO Inc. for a five-year period. This partnership further strengthens Mauna Kea Technologies' ties with the Japanese market, and is a major step forward in the company's efforts to obtain regulatory approval in the world's second largest endoscopy device market after the US.
New Data on Cellvizio Presented at DDW 2013 Suggests That Optical Biopsies May Help Confirm and Rule Out Pancreatic Cystic Tumors*
Marketwire - Wed May 22, 10:45AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced that optical biopsies using a microscope so tiny it fits through a small needle show clear cellular-level images inside pancreatic cysts, which could assist physicians in the diagnosis of pancreatic cystic tumors and help patients with benign cysts avoid unnecessary surgery, according to new data presented at Digestive Disease Week 2013, which concludes here today.
Mauna Kea Technologies Announces Strongest Scientific Exposure Ever With More Than 40 Communications on Cellvizio(R) at Digestive Disease Week 2013
Marketwire - Fri May 17, 12:30AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced that 41 presentations at Digestive Disease Week (DDW) 2013 will highlight the use of optical biopsy across many of the most pervasive diseases in the gastrointestinal tract. Sixteen of the communications will be delivered through oral presentations and seven presentations will focus on needle-based optical biopsies, the newest application of Cellvizio technology that allows physicians to see cellular structures inside pancreatic cysts in the digestive tract in real time. DDW 2013 runs from May 18 to 21 in Orlando.
Mauna Kea Technologies gets FDA approval to market AQ-Flex 19 miniprobe for fine needle aspiration procedures
M2 - Tue Apr 30, 12:01PM CDT
Mauna Kea Technologies (Euronext Paris:MKEA), a medical device company focused on the optical biopsy market, confirmed today that the US Food and Drug Administration (FDA) has cleared the AQ-Flex 19 miniprobe to provide real-time optical biopsies during endoscopic ultrasound-guided fine needle aspiration (EUSFNA) procedures in the digestive tract.
FDA Grants Mauna Kea Technologies 510(k) Clearance to Market AQ-Flex(TM) 19 Miniprobe for Fine Needle Aspiration Procedures
Marketwire - Tue Apr 30, 9:39AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the AQ-Flex(TM) 19 miniprobe to provide real-time optical biopsies during endoscopic ultrasound-guided fine needle aspiration (EUSFNA) procedures in the digestive tract. This represents the sixth U.S. regulatory clearance for Mauna Kea Technologies' Cellvizio or one of its dedicated miniprobes, which already obtained the CE mark in Europe.
Mauna Kea Technologies Announces Highlights of 5th Annual International Conference of Cellvizio(R) Users (ICCU)
Marketwire - Tue Apr 23, 10:45AM CDT
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced highlights from the 5th Annual International Conference of Cellvizio Users (ICCU) held in Versailles, France, from April 5 to 7. Over 200 international optical biopsy experts -- a 70% increase in attendance over the 2012 meeting -- representing 17 countries and a variety of specialties including digestive endoscopy, pulmonology, urology, surgery, otorhinolaryngology, pathology and pre-clinical research gathered to review and discuss the latest research and impact of optical biopsy on clinical care.
Mauna Kea Technologies Reports First Quarter 2013 Sales Up 11% to EUR 1.8m
Marketwire - Tue Apr 16, 10:45AM CDT
Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio(R), the fastest way to see cancer, today announced its sales for the first quarter of the year ended March 31, 2013.
(0)
(0)Mauna Kea Technologies (MKEAF) Stock Research Links
Scroll down for more posts ▼